Re: [Histonet] FW: [IHCRG] Very important question!!!!!!!!!!!!!!! !
Mr. Houston has a good point. We have actually included this in a comment
that will be on all of our EGFR reports.
> The clinical trials that gained FDA approval for Erbitux were based on
> positivity with the DakoCytomation EGFR pharmDx kit. It gives some creedence
> to the story that insurance companies will not pay for the drug unless this
> specific kit is used; certainly in the embryonic status of the drug's usage.
> It should be added though, that during the clinical trials no-one with a
> negative result by IHC was included in the study. Oncologists are asking
> whether there is a need to order the test. Perhaps those "negative" patients
> will also beneficially respond to Erbitux. There is no evidence to suggest
> they won't.
> Ronnie Houston
> Director of Anatomic Pathology
> Bon Secours HealthPartners Laboratories
> 5801 Bremo Road
> Richmond, VA 23226
> (804) 287 7972
> (804) 287 7906 - fax
> -----Original Message-----
> From: DDittus787@aol.com [mailto:DDittus787@aol.com]
> Sent: Friday, March 05, 2004 3:06 PM
> To: firstname.lastname@example.org; email@example.com
> Subject: Re: [Histonet] FW: [IHCRG] Very important
> question!!!!!!!!!!!!!!! !
> I have heard this stuff before ie: herceptest,however i am very aware of the
> hcfa form used in billing (it is universal-all over the country)and nowhere
> does it ask what test method!!!! now i think it might be wise to run some
> correlation studies with the dako kit, but the antibody egfr has been around
> longer than erbitux and from many manufacturers, and all that said one has
> to do whats best for ones lab and with the pathologists approval. i run a
> different clone for her2 and i run cd117 for another monoclonal
> therapy(gleevic) and all patients are receiving according to their doctors
> whatever they need and were getting paid, and yes there is full disclosure
> on our reports. just my 2 cents
> Histonet mailing list
> The information in this communication is intended to be confidential to the
> Individual(s) and/or Entity to whom it is addressed.
> It may contain information of a Privileged and/or Confidential nature, which
> is subject to Federal and/or State privacy regulations.
> In the event that you are not the intended recipient or the agent of the
> intended recipient, do not copy or use the information
> contained within this communication, or allow it to be read, copied or
> utilized in any manner, by any other person(s). Should
> this communication be received in error, please notify the sender immediately
> either by response e-mail or by phone at 410-442-3250,
> and permanently delete the original e-mail, attachment(s), and any copies.
> Histonet mailing list
Histonet mailing list
<< Previous Message | Next Message >>